Novo Nordisk (NVO) makes Ozempic, the best-known GLP-1 drug out today. And until quite recently, the Danish pharma giant ...

Eli Lilly's growth is impressive, but its current valuation is only justifiable with sustained high growth. Click here to ...

The global weight-loss drug market is experiencing exceptional growth, projected to expand from around $144.6 billion in 2023 ...

Lilly dominates GLP-1 market but faces near-term headwinds, while AstraZeneca boasts steady growth, rising estimates and a higher dividend yield.

Aimee Chapman's pursuit of weight loss through Mounjaro led to a harrowing health crisis. The Southampton woman experienced ...

In the marketing effort promoting Lilly’s Mounjaro, Stonestreet and his mother, Jamey, discuss living with type 2 diabetes and taking the GLP-1 for treatment.

Thai healthcare solutions company Zuellig Pharma has announced that Mounjaro (tirzepatide), Eli Lilly’s (NYSE: LLY) ...

Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), GE Aerospace ...

Eli Lilly (NYSE: LLY) is one of the undisputed leaders in developing anti-obesity medicines, with Novo Nordisk (NYSE: NVO) ...

Eli Lilly & Co. (LLY) shares have come under significant pressure in late May following a pivotal decision by CVS Health's ...

Global pharmaceutical giant Eli Lilly & Co. is seeking tax incentives for a potential 236-acre biomanufacturing plant in ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.